

Special Issue

Host Targeted Therapeutics against Virus Infections

Message from the Guest Editors

The current Covid-19 pandemic and the frequent emergence and re-emergence of novel viruses highlights the urgent need for effective antivirals. The fact that every virus needs host cells to replicate sparked increasing interest in host-directed drugs that act as antivirals (host-targeted antivirals, HTA). While this approach had been heavily debated 20 years ago, the idea to target host functions for antiviral therapy was boosted due to technical developments such as cell-omics approaches and has now become widely accepted. (inhibitors of cell signaling pathways have received special attention in this respect). In this Special Issue, we want to summarize the latest findings in this field and would like to encourage research groups working on host-targeted antivirals to submit their latest findings.

Guest Editors

Prof. Dr. Oliver Planz
Prof. Dr. Stephan Ludwig
Prof. Dr. Stephan Pleschka

Deadline for manuscript submissions

closed (31 December 2022)



Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/73501

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)





Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)



About the Journal

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Viruses* (ISSN 1999-4915). *Viruses* is published in open access format—research articles, reviews and other content are released on the internet immediately after acceptance. The scientific community and the general public have unlimited free access to the content as soon as it is published. As an open access journal, *Viruses* is supported by the authors or their institutes by payment of article processing charges (APC) for accepted papers. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research,
National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.2 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the second half of 2025).